OBJECTIVES: Recent studies suggest that Androgen-Deprivation-Therapy is associated with increased risk for patients with hormone-sensitive prostate cancer (PCa) and pre-existing cardiovascular (CV) disease. Hereunder, the slightly more expensive GnRH-antagonist shows a beneficial risk profile over GnRH-agonists. Therefore the objective of the present study was to assess the cost-effectiveness of degarelix compared to GnRH-agonists for PCa-patients with pre-existing CV disease. METHODS: This analysis is based on a pooled analysis of six Phase III-RCTs comparing GnRH-agonists with degarelix addressing CV-events in PCa-patients (Albertsen et al.